Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on

International Journal of Clinical Practice
J Usher-SmithM Kirby

Abstract

This short report was designed to provide 2-year follow-up data from a previous study carried out in a primary care practice in the UK to assess the clinical and practical implications of switching to generic drugs. All patients previously switched from atorvastatin to simvastatin or losartan to candesartan were reviewed retrospectively 2 years after the switch. Total serum cholesterol and clinic blood pressure readings were used along with records of cardiovascular events occuring during the 2 year period to assess the clinical impact of the switch. Of the 69 patients switched from atorvastatin to simvastatin between March and September 2005, 65 are still registered at the practice. Of these, 61 (94%) are still on simvastatin and 58 (89%) on the same dose. There was no significant change in mean total cholesterol over this 2 year period [between 4.04 +/- 0.52 mmol/l prior to the switch and 3.90 +/- 0.63 mmol/l 2 years after the switch (p = 0.06)]. Of the 108 patients switched from losartan to candesartan, 94 are still registered at the practice and taking an angiotensin receptor blocker (ARB), 92 of these (98%) are still on candesartan and there was a significant reduction in blood pressure 2 years post-switch [between 138/79 ...Continue Reading

References

Jul 16, 2003·The American Journal of Cardiology·Peter H JonesUNKNOWN STELLAR Study Group
Jan 9, 2007·Lancet·Luca Mascitelli, Francesca Pezzetta
Jan 9, 2007·Lancet·Rob Butler, James Wainwright
Feb 27, 2007·Lancet·James C MoonRubin Minas

❮ Previous
Next ❯

Citations

Feb 12, 2008·International Journal of Clinical Practice·R MinhasJ C Moon
Aug 21, 2009·International Journal of Clinical Practice·C NormanB Wettermark
Jul 27, 2010·International Journal of Clinical Practice·V J WilleyM J Cziraky
Jan 18, 2011·International Journal of Clinical Practice·A S Wierzbicki
Nov 19, 2013·Journal of Comparative Effectiveness Research·Marija KalabaRichard E Malmström
Nov 19, 2013·Journal of Comparative Effectiveness Research·Brian GodmanSteven Simoens
Dec 19, 2013·Journal of Comparative Effectiveness Research·Andrew MartinMarion Bennie
Jun 12, 2013·Applied Health Economics and Health Policy·Brian GodmanLars L Gustafsson
Oct 10, 2013·Applied Health Economics and Health Policy·Ulrik HesseRickard E Malmström
Nov 15, 2015·Expert Review of Pharmacoeconomics & Outcomes Research·Joseph O FadareBrian Godman
Oct 29, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Wenjie ZengBrian Godman
Oct 21, 2010·Expert Opinion on Pharmacotherapy·Vasilios G AthyrosDimitri P Mikhailidis
Feb 10, 2010·Current Medical Research and Opinion·J SignorovitchK H Kahler
May 8, 2013·Current Medical Research and Opinion·Terry A JacobsonMark Cziraky
Apr 7, 2009·Current Medical Research and Opinion·Richard H ChapmanMichael B Nichol
Feb 5, 2009·Annals of Medicine·Dan AtarRichard Hobbs
Jul 8, 2015·Basic & Clinical Pharmacology & Toxicology·Elisabetta PoluzziFabrizio De Ponti
Aug 19, 2010·British Journal of Clinical Pharmacology·Martin G Duerden, Dyfrig A Hughes
Apr 1, 2015·Journal of Comparative Effectiveness Research·Ilse TruterBrian Godman
Jan 23, 2015·BMC Health Services Research·Wenjie ZengBrian Godman
Apr 21, 2016·Journal of Comparative Effectiveness Research·Onyinye Onyeka AkunneJoseph Fadare
Oct 24, 2014·Frontiers in Pharmacology·James C MoonRickard E Malmström
Jan 1, 2009·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Rob SelzerMichael McGartland
Feb 4, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·Diane McGinnAlan Haycox
Aug 13, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Luka VončinaLars L Gustafsson
Jan 28, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Mohammed AbuelkhairLars L Gustafsson
Nov 29, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Vanda Markovic-PekovicLars L Gustafsson
Dec 21, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Anna BucsicsRickard E Malmström
Apr 11, 2012·American Journal of Therapeutics·Dan AtarPeter J Lansberg
Mar 1, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Brian GodmanAlan Haycox
Jan 28, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Marion BennieStephen Campbell
Nov 28, 2009·Expert Review of Pharmacoeconomics & Outcomes Research·Anna ComaAlan Haycox
Oct 24, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Brian GodmanIlse Truter

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.